<DOC>
	<DOCNO>NCT01011166</DOCNO>
	<brief_summary>This study ass short term safety , antiviral activity pharmacokinetics ( PK ) IDX184 combination Peg-interferon ( Peg-IFN ) /Ribavirin ( RBV ) participant hepatitis C virus ( HCV ) genotype ( GT ) 1 infection . These data guide dose selection future , long term study .</brief_summary>
	<brief_title>Safety Antiviral Activity IDX184 Combination With Pegylated Interferon Ribavirin ( MK-2355-004 )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Has document chronic HCV GT1 infection Agrees use doublebarrier contraception male agree donate sperm first dose study therapy least 6 month final dose study therapy Has receive previous antiviral treatment HCV infection Has cirrhosis decompensated liver disease Is pregnant breastfeeding Is coinfected hepatitis B virus ( e.g. , hepatitis B surface antigen [ HBsAg ] positive ) and/or human immunodeficiency virus ( HIV ) Has clinically significant concomitant disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>HepC</keyword>
	<keyword>Hep C</keyword>
</DOC>